Brodalumab: Six-Year US Pharmacovigilance Report

Dermatol Ther (Heidelb). 2024 Nov 26. doi: 10.1007/s13555-024-01304-y. Online ahead of print. ABSTRACT INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are...